![]() |
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
Sponsors and Collaborators: |
National Institute on Drug Abuse (NIDA) University of Minnesota |
---|---|
Information provided by: | National Institute on Drug Abuse (NIDA) |
ClinicalTrials.gov Identifier: | NCT00000293 |
The purpose of this study is to determine the effect of nefazodone on relapse to cocaine use in depressed and non-depressed females with cocaine abuse/dependence.
Condition | Intervention | Phase |
---|---|---|
Cocaine-Related Disorders |
Drug: Nefazodone |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Double-Blind, Placebo Control |
Official Title: | Effect of Nefazodone on Relapse in Females With Cocaine Abuse |
Estimated Enrollment: | 0 |
Study Start Date: | January 1999 |
Estimated Study Completion Date: | December 2001 |
The purpose of this study is to determine the effect of nefazodone on relapse to cocaine in women and if a greater effect will be seen in the dependent condition. A relapse and coping skills questionnaire will be utilized to determine the various factors important to the relapse process.
Ages Eligible for Study: | 18 Years to 55 Years |
Genders Eligible for Study: | Female |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Female, ages 18-55, cocaine abuse/dependence, use of cocaine 7 days of the last 30 days or of the 30 days prior to current abstinence, less than 90 days current abstinence, at least an 8th grade education.
Exclusion Criteria:
Unstable medical conditions; current use of Hismanal, Seldane, or Propulsid; dx of MR, OBS, bipolar, schizophrenia.
United States, Minnesota | |
University of Minnesota | |
Minneapolis, Minnesota, United States, 55455 |
Principal Investigator: | Dorothy Hatsukami, Ph.D. | University of Minnesota |
Study ID Numbers: | NIDA-09259-10, P50-09259-10 |
Study First Received: | September 20, 1999 |
Last Updated: | August 16, 2005 |
ClinicalTrials.gov Identifier: | NCT00000293 |
Health Authority: | United States: Federal Government |
Cocaine-Related Disorders Nefazodone Mental Disorders |
Substance-Related Disorders Disorders of Environmental Origin Cocaine |
Therapeutic Uses Psychotropic Drugs Antidepressive Agents, Second-Generation |
Central Nervous System Agents Pharmacologic Actions Antidepressive Agents |